**Supplemental Table 1 – KIR/KIR-ligand (HLA-C) interaction frequencies in LNM+ BC patients and healthy controls with comparisons.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **KIR genes and**  **HLA ligands** | **LNM+**  **BC PATIENTS**  **(N=21)** | | **FEMALE CONTROLS**  **(N=38)** | | **P-value=** | **OR=** | **MIXED**  **CONTROLS**  **(N=63)** | | **P=** | **OR=** |
| **N** | **%** | **N** | **%** |  |  | **N** | **%** |  |  |
| 2DL1 HLA-C2+ | 14 | 66.7 | 28 | 73.7 | NS |  | 43 | 68.3 | NS |  |
| 2DL1 HLA-C1+ | 13 | 61.9 | 28 | 73.7 | NS |  | 46 | 73.0 | NS |  |
| 2DL2 HLA-C1+ | 7 | 33.3 | 17 | 44.7 | NS |  | 28 | 44.4 | NS |  |
| **2DL2 HLA-C1/C1** | **7** | **33.3** | **4** | **10.5** | **0.042** | **4.250** | **7** | **11.1** | **0.042** | **4.000** |
| 2DL2 HLA-C2/C2 | 3 | 14.3 | 9 | 23.7 | NS |  | 11 | 17.5 | NS |  |
| 2DL2 HLA-C1/C2 | 3 | 14.3 | 13 | 34.2 | NS |  | 20 | 31.7 | NS |  |
| **2DL2 HLA-C2+** | **5** | **23.8** | **22** | **57.9** | **0.015** | **0.227** | **31** | **49.2** | **0.047** | **0.323** |
| 2DL3 HLA-C1+ | 13 | 61.9 | 23 | 60.5 | NS |  | 49 | 77.8 | NS |  |
| 2DL3 HLA-C1/C1 | 6 | 28.6 | 9 | 23.7 | NS |  | 20 | 31.7 | NS |  |
| 2DL3 HLA-C2+ | 14 | 66.7 | 20 | 52.6 | NS |  | 43 | 68.3 | NS |  |
| 2DS1 HLA-C2+ | 6 | 28.6 | 14 | 36.8 | NS |  | 22 | 33.3 | NS |  |
| 2DS1 HLA-C2/C2 | 2 | 9.5 | 6 | 15.7 | NS |  | 8 | 12.7 | NS |  |
| 2DS1 HLA-C1+ | 8 | 38.1 | 12 | 31.6 | NS |  | 21 | 33.3 | NS |  |
| **2DS5 HLA-C2+** | 3 | **14.3** | 12 | 31.6 | NS |  | 40 | **63.5** | **0.000**1 | **0.096** |
| 2DL2 and 2DS2+, HLA-C2 | 4 | 19.0 | 17 | 44.7 | 0.087 |  | 24 | 38.1 | NS |  |
| **2DL2- 2DS4INS-** | **13** | **61.9** | **9/39** | **23.1** | **0.007** | **5.417** | **21/66** | **31.8** | **0.028** | **3.482** |
| **2DL2- 2DS4INS- HLA-C2+** | **9** | **42.9** | **4** | **10.5** | **0.008** | **6.375** | **11** | **17.5** | **0.038** | **3.546** |